Polyrizon Ltd. (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces  the signing of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading European-based Good Manufacturing Practice (GMP) manufacturer. This collaboration will supply Clinical Trial Material (CTM) for Polyrizon’s PL-14 allergy blocker, in preparation for a clinical trial that is expected to commence in 2025.

With this agreement, Polyrizon secures a reliable and compliant manufacturing source for the PL-14 clinical trial. The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker, advancing Polyrizon's mission to address allergy-related health issues through unique nasal sprays.

“We are pleased to have established this partnership with Eurofins CDMO Amatsiaquitaine S.A.S, which strengthens our preparation efforts for the upcoming PL-14 clinical trial," said Tomer Izraeli, CEO of Polyrizon. "We believe that this collaboration marks a significant milestone in our journey toward providing effective allergy protection solutions to patients."

The manufacturing site is set to support the CTM needs for Polyrizon's planned 2025 trial, offering high-quality and compliant development programs in line with USA and European regulatory standards.